|
Frequencies of CBC patients carrying pathogenic DNA-damage repair pathway and ATM missense mutations |
|||||||||
| Parameter |
All CBC patients (n = 247) |
Previous RT (n = 169) |
No RT (n = 78) |
Carriers versus non-carriers |
|||||
| n |
Percentage |
n |
Percentage |
n |
Percentage |
OR for CBC after RT |
95% CI |
p |
|
|
|
|||||||||
| DDRP mutated |
51 |
21 |
41 |
24.3 |
10 |
12.8 |
2.18 |
1.03–4.62 |
0.043 |
| All patients with only a pathogenic DDRP mutation |
37 |
15 |
29 |
17.2 |
8 |
10.3 |
1.8 |
0.79–4.17 |
|
| Patients with both a pathogenic DDRP and an ATM missense mutation |
14 |
5.7 |
12 |
7.1 |
2 |
2.6 |
2.90 |
0.63–13.30 |
|
| Patients with only an ATM missense mutation |
29 |
11.7 |
21 |
12.4 |
8 |
10.3 |
1.24 |
0.52–2.94 |
|
|
Results for all contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure, are presented. Odds ratio (OR) and 95% confidence interval (CI) are given for mutation carriers versus non-carriers to develop radiation-associated breast cancer. DDRP, DNA-damage repair pathway; RT, radiation treatment. | |||||||||
Broeks et al. Breast Cancer Research 2007 9:R26 doi:10.1186/bcr1668 |
|||||||||